Natural source materials often contain trace amounts of therapeutic molecules that are difficult to isolate or utilize effectively. Increasing the yield and purity of these specific chemical constituents addresses the limitation of low natural abundance for pharmacological use.

Off-target effects and systemic toxicity limit the efficacy of bioactive compounds. Improving site-specific action reduces collateral damage to healthy tissues.

Off-target binding and systemic toxicity in pyrazolopyrimidine scaffolds. Enhancing target specificity reduces adverse side effects in therapeutic applications.

Natural compounds like forsythiaside are being optimized to address the lack of effective treatments for evolving viral mutations and blood clotting disorders. Overcoming these therapeutic gaps provides a critical advantage in treating complex infectious and cardiovascular pathologies.